March 25, 2025 06:30 AM EDTUpdated 07:46 AM
Deals
China
Pharma

Mer­ck strikes deal for heart drug, worth up to $2B, with Chi­na’s Hen­grui

Drew Armstrong

Executive Editor

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US

An­oth­er im­munol­o­gy biotech emerges as Hill­star takes flight with $67M

Kezar toplines small Phase 2a dataset in au­toim­mune liv­er dis­ease

Oph­thal­mol­o­gy start­up Char­ac­ter Bio­sciences gets $93M for ge­net­ics-based ap­proach

Ab­b­Vie files trade se­crets suit against ADC com­peti­tor

Three ma­jor ques­tions on phar­ma tar­iffs Trump claims are on the way

A service from the Financial Times